Moderna–Recordati Strike Global Deal on mRNA-3927 for Propionic Acidemia
Moderna–Recordati Strike Global Deal on mRNA-3927 for Propionic Acidemia Moderna and Recordati Partner to Bring First mRNA Treatment for Rare Metabolic Disorder to Patients BLUF (Bottom Line Up Front): Moderna has partnered with Italian pharmaceutical company Recordati to develop and commercialize mRNA-3927, an investigational mRNA-based treatment for propionic acidemia (PA)—a devastating rare genetic disorder affecting metabolism. This marks a significant expansion of mRNA technology beyond vaccines into treating genetic diseases, with the therapy currently in Phase 1/2 clinical trials. The agreement provides Moderna with up to $160 million in upfront and near-term payments, while Recordati will handle global commercialization once approved. For patients with PA and their families, this represents the first potential disease-modifying treatment for a condition that currently has only supportive care options. Understanding Propionic Acidemia: A Devastating Genetic Disorder Propion...